

AMENDMENT

U.S. Appln. No. 09/915,543

IN THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

Claims 1-70. (Cancelled).

Claim 71. (Currently Amended) An isolated polypeptide comprising:

(i) a peptide consisting of amino acids 177 to 204 of SEQ ID NO:15, ~~wherein said peptide inhibits tef driven luciferase activity in colon cancer cells,~~

~~(ii) a peptide having at least 90% amino acid sequence identity to said (i), wherein said peptide inhibits tef driven luciferase activity in colon cancer cells, or~~

~~(iii) a peptide consisting of amino acids 349 to 383 of SEQ ID NO:15, wherein said peptide inhibits tef driven luciferase activity in colon cancer cells or~~

~~(iv) a peptide having at least 90% amino acid sequence identity to said (iii),~~

~~-wherein said isolated polypeptide does not comprise both of said peptide (i) and (ii), and said isolated polypeptide inhibits tcf-driven luciferase activity in colon cancer cells,~~

~~wherein said isolated polypeptide inhibits tef drive luciferase activity in colon cancer cells.~~

AMENDMENT

U.S. Appln. No. 09/915,543

Claim 72. (Cancelled).

Claim 73. (Previously Presented) A chimeric molecule comprising the polypeptide of Claim 71 fused to a heterologous polypeptide.

Claim 74. (Cancelled).

Claim 75. (Previously Presented) The chimeric molecule according to Claim 73, wherein said heterologous polypeptide is selected from the group consisting of an antigenic epitope, glutathione-S-transferase, thioredoxin, and antibody.

Claim 76. (Cancelled).

Claim 77. (Previously Presented) A pharmaceutical composition comprising the polypeptide of Claim 71, and a pharmaceutically acceptable carrier.

Claim 78. (Cancelled).

Claim 79. (New) An isolated polypeptide comprising:

(i) a peptide having at least 90% amino acid sequence identity to a peptide consisting of amino acids 177 to 204 of SEQ ID NO:15 and which binds to Doll, or

(ii) a peptide having at least 90% amino acid sequence identity to a peptide consisting of amino acids 349 to 383 of SEQ ID NO:15 and which binds to β -Cat,

wherein said isolated polypeptide does not comprise both of said peptide (i) and (ii), and said isolated polypeptide inhibits tcf-driven luciferase activity in colon cancer cells.

Claim 80. (New) A chimeric molecule comprising the polypeptide of Claim 79 fused to a heterologous polypeptide.

AMENDMENT

U.S. Appln. No. 09/915,543

Claim 81. (New) The chimeric molecule according to Claim 80, wherein said heterologous polypeptide is selected from the group consisting of an antigenic epitope, glutathione-S-transferase, thioredoxin, and antibody.

Claim 82. (New) A pharmaceutical composition comprising the polypeptide of Claim 79, and a pharmaceutically acceptable carrier.